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The need to differentiate Campylobacter
fetus subspecies isolated from humans
The recent review in Clinical Microbiology and
Infection by Butzler [1] described how collabor-
ation between medical doctors and their veterin-
ary colleagues during the 1970s led to the
discovery of Campylobacter enteritis. Nowadays,
Campylobacter spp. are a leading cause of food-
borne illness in the industrialised world. Campy-
lobacter jejuni and Campylobacter coli are the most
frequent species isolated from humans. However,
the public health burden of other Campylobacter
spp., such as Campylobacter fetus, remains
unmeasured [1]. C. fetus is thought to be an
underdiagnosed cause of human disease because
of its fastidious requirements for growth media
and incubation atmosphere. In particular, select-
ive media used routinely for the isolation of
Campylobacter spp. contain antibiotics such as
cephalothin and cefoperazone, to which C. fetus
can be susceptible [2].
The species C. fetus is divided into subspecies
fetus (Cff) and venerealis (Cfv) on the basis of their
biochemical differences [3]. Cff is recovered com-
monly from the gastrointestinal tract of animals,
including food-producing animals, but has also
been isolated occasionally from local and systemic
infections in humans [4]. In contrast, Cfv appears
to be adapted to the bovine genital tract, where it
causes bovine genital campylobacteriosis. There
are only seven reported cases of its isolation from
human patients: from the stools of two homosex-
ual men; from two women with bacterial vagino-
sis; and from blood and other, non-deﬁned,
samples from three patients [4–7]. The only
accepted phenotypic method for subspeciation
in routine laboratories is the glycine tolerance
assay [3]. In contrast to Cff, Cfv fails to grow on
media containing glycine 1% w ⁄ v, although some
glycine-tolerant variants of Cfv (biovar interme-
dius) have been reported [6,8]. Glycine tolerance
can be mediated by bacteriophages or sponta-
neous mutation, and may be highly dependent on
the methods used [9,10]. Recommendations exist
for performing glycine testing, but have not yet
been adopted widely [10]. Commonly, clinical
cases of C. fetus infection are reported following
subspeciation by commercially available identiﬁ-
cation systems that do not contain the glycine
tolerance test, or by molecular methods such as
16S rDNA and 16S rRNA sequencing that do not
determine the subspecies adequately [7,11–13].
Pulsed-ﬁeld gel electrophoresis (PFGE)-DNA
numerical analysis, ampliﬁed fragment length
polymorphism (AFLP) analysis and PCR are
effective methods for differentiating subspecies
of C. fetus [7,14,15]. However, in a few cases, the
results of subspeciation by AFLP and PFGE-DNA
numerical analysis do not correlate with the
results of biochemical and PCR typing, suggest-
ing that distinct strains may be evolving in other
geographical regions [7,14,16].
C. fetus may potentially be a new emerging
zooanthroponotic pathogen, because the popula-
tion at risk for systemic infections is increasing
worldwide. The signiﬁcance of international ani-
mal trade, and its relevance to the epidemiology
of infectious disease in humans, has not yet been
investigated extensively. Changes in food con-
sumption in industrialised countries, with a trend
towards undercooked or raw foods and unpas-
teurised milk, augment the risk of exposure to
C. fetus, and might result in a change in its habitat
[2]. Resistance to quinolones has been described,
and relapse after termination of antibiotic therapy
is a frequent occurrence [2,17].
Following collaborative efforts, we recently
identiﬁed the ﬁrst human isolate of C. fetus from a
patient with underlying liver cirrhosis suffering
from pneumonia-associated bacteraemia. This iso-
late was identiﬁed as Cfv by phenotypingmethods
and as Cff by AFLP and PCR (data available from
corresponding author). Given that C. fetus contin-
ues to be considered as an underdiagnosed zoo-
anthroponotic emerging human pathogen, and
that subspecies discrimination remains challen-
ging, we recommend that identiﬁcation of human
isolates of C. fetus should be performed in special-
ised diagnostic and veterinary laboratories by
genotyping methods, such as AFLP, in addition
to phenotyping, in order to build up a database for
monitoring any change in habitat and to determine
the true public health burden.
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